title: Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.
abstract: Patients with metastatic hormone refractory prostate cancer (HRPC) have limited treatment options and new therapies are needed. Advances in the understanding of the molecular mechanisms implicated in prostate cancer progression have identified many potential therapeutic gene targets including Bcl-2, an important pro-survival regulator of apoptotic cell death. Bcl-2 is overexpressed in a variety of human malignancies including prostate cancer where it has also been associated with androgen independent progression and treatment resistance. Oblimersen is a phosphorothioate antisense oligonucleotide complimentary to the Bcl-2 mRNA and a potent inhibitor of Bcl-2 expression which in pre-clinical testing can significantly enhance the therapeutic effect of chemotherapy, hormone and radiation therapy. Clinical trials evaluating oblimersen in combination with chemotherapy in a variety of cancers have shown good tolerability and promising response rates. Randomized trials are required to determine if oblimersen can enhance the effectiveness of docetaxel in patients with HRPC.
authors.affiliation: BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada. kchi@bccancer.bc.ca
authors.forename: Kim N
authors.initials: KN
authors.lastname: Chi
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D018390:Gene Targeting / Q000379:methods*; D019254:Genes, bcl-2 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D013873:Thionucleotides / Q000627:therapeutic use*
chemical_list: D013873:Thionucleotides; C408162:oblimersen
references.citation: Am J Pathol. 1993 Aug;143(2):390-400
references.pmid: 7688182
references.citation: Ann Oncol. 2001 Sep;12(9):1273-9
references.pmid: 11697840
references.citation: Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):133-4
references.pmid: 9593052
references.citation: Clin Cancer Res. 2002 Aug;8(8):2530-5
references.pmid: 12171880
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: J Clin Oncol. 1999 Sep;17(9):2941-53
references.pmid: 10561374
references.citation: Proc Natl Acad Sci U S A. 1978 Jan;75(1):280-4
references.pmid: 75545
references.citation: J Pharmacol Exp Ther. 2001 Sep;298(3):934-40
references.pmid: 11504787
references.citation: Cancer Res. 1995 Oct 1;55(19):4438-45
references.pmid: 7671257
references.citation: Am J Pathol. 1996 May;148(5):1557-65
references.pmid: 8623924
references.citation: Breast Cancer Res Treat. 2000 Oct;63(3):199-212
references.pmid: 11110054
references.citation: Cancer Res. 1999 Aug 15;59(16):4030-4
references.pmid: 10463603
references.citation: J Urol. 1999 Jul;162(1):12-6; discussion 16-7
references.pmid: 10379729
references.citation: J Natl Cancer Inst. 2000 Jan 5;92(1):34-41
references.pmid: 10620631
references.citation: N Engl J Med. 2004 Oct 7;351(15):1513-20
references.pmid: 15470214
references.citation: J Clin Oncol. 1999 Aug;17(8):2506-13
references.pmid: 10561316
references.citation: Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002
references.pmid: 9560217
references.citation: Cancer Res. 1999 Nov 1;59(21):5429-32
references.pmid: 10554011
references.citation: J Clin Oncol. 1996 Jun;14(6):1756-64
references.pmid: 8656243
references.citation: Cell Death Differ. 1998 May;5(5):372-80
references.pmid: 10200486
references.citation: Clin Cancer Res. 2001 Dec;7(12):3920-7
references.pmid: 11751483
references.citation: Cancer Res. 1992 Dec 15;52(24):6940-4
references.pmid: 1458483
references.citation: Clin Cancer Res. 2002 Mar;8(3):679-83
references.pmid: 11895895
references.citation: J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
references.pmid: 15173273
references.citation: Nat Med. 1998 Feb;4(2):232-4
references.pmid: 9461199
references.citation: Cancer Res. 1997 Jan 15;57(2):229-33
references.pmid: 9000560
references.citation: J Clin Oncol. 2000 May;18(9):1812-23
references.pmid: 10784621
references.citation: Nature. 1997 Jun 19;387(6635):773-6
references.pmid: 9194558
references.citation: Cell. 1997 Nov 28;91(5):559-62
references.pmid: 9393848
references.citation: Clin Cancer Res. 2001 Aug;7(8):2537-44
references.pmid: 11489837
references.citation: Clin Cancer Res. 2000 Jul;6(7):2891-902
references.pmid: 10914739
references.citation: Clin Cancer Res. 2000 Jun;6(6):2492-500
references.pmid: 10873104
references.citation: Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213
references.pmid: 12162702
references.citation: Proc Natl Acad Sci U S A. 1977 Oct;74(10):4370-4
references.pmid: 270678
references.citation: Br J Cancer. 1998 Oct;78(8):1035-42
references.pmid: 9792147
references.citation: J Urol. 1997 Feb;157(2):569-74
references.pmid: 8996359
references.citation: Int J Cancer. 2001 Mar 15;91(6):846-50
references.pmid: 11275990